HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

VVOS

Vivos Therapeutics, Inc. (NASDAQ)

Healthcare — Medical Devices

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

None 3 analysts
$0.49
$-0.01 (-2.47%)
Target: $2.45 (404.4%)
Sign in to add VVOS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$6.75M
P/E Ratio (TTM)-
Forward P/E-0.58
EPS (TTM)$-2.14
Dividend Yield-
Profit Margin-127.70%
Revenue Growth70.50%
ROE-1599.81%
Debt/Equity-
Recommendation None
Analyst Target$2.45
Analysts3
Indexes NASDAQ

Technical Indicators

RSI (14)36.4
Beta6.08
SMA 20-
SMA 40-
52-Week High$7.95
52-Week Low$0.38
50-Day Avg$0.66
200-Day Avg$1.73
Avg Volume$1.75M
Volume30.1K

Performance Analysis

NEUTRAL

VVOS presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.38), which could present a value opportunity.
~ RSI at 36.4 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ Strong revenue growth of 70.5% year-over-year.
- Operating at a loss with -127.7% margin.
~ Wall Street consensus is "none" from 3 analysts.
+ Average analyst target of $2.45 implies 404.4% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:37 UTC

Back to Screener Export Report